Mar 11, 2020 / 07:50PM GMT
Jack Meehan - Barclays Bank PLC, Research Division - VP & Senior Research Analyst
Thank you and good afternoon. This is Jack Meehan with the Barclays Life Science Tools and Diagnostics team. Pleased to be joined now with Repligen and glad they are joining us in this virtual format with CFO, Jon Snodgres, as well as Head of Investor Relations, Sondra Newman. Thank you, again, and Jon, Sondra, would you like to make any introductory comments?
Jon K. Snodgres - Repligen Corporation - CFO & Secretary
Yes, we sure would. Thank you, Jack, and pleasure to be here, and thank you guys for continuing the conference virtually.
So quickly, I'll give you an overview of Repligen. For those of you who may not know this -- know us, Repligen is a leading innovator and supplier into the fast-growing bioprocessing market, where we supply products to large biopharmaceutical, CDMO, gene and cell therapy, and other types of customers on a worldwide basis. The overall bioprocessing market that we look at is about $10 billion annually and is expected to grow at an 8%
Repligen Corp at Barclays Global Healthcare Conference Transcript
Mar 12, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers